Treatment of suction termination of pregnancy-retained products with misoprostol markedly reduces the repeat operation rate.
A six-year audit of clinical outcomes following the treatment of suction termination of pregnancy-retained products of conception symptoms with 200 microg of misoprostol orally or sublingually three times a day for six doses showed that it was 93% effective and it reduced the repeat dilation and curettage rate by 79.6% (P < 0.001).
Chambers
Dennis G
DG
The Queen Elizabeth Hospital Pregnancy Advisory Centre, Woodville Park, Adelaide, 21 Belmore Terrace, Woodville Park, SA 5011, Australia. dennis.chambers@health.sa.gov.sa
Mulligan
Ea C
EC
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000028:Abortion, Induced / Q000009:adverse effects*; D000286:Administration, Sublingual; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage*; D017060:Patient Satisfaction; D011247:Pregnancy; D012189:Retrospective Studies; D017211:Treatment Failure; D014619:Vacuum Curettage / Q000009:adverse effects*
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol